315 related articles for article (PubMed ID: 33954979)
1. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
2. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.
Meihandoest T; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Amstutz U; Bovet C; Sauter TC; Asmis LM; Nagler M
Front Cardiovasc Med; 2022; 9():817826. PubMed ID: 35369293
[TBL] [Abstract][Full Text] [Related]
4. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
5. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
7. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
8. Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator.
Burger A; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Binder NB; Nagler M
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37371023
[TBL] [Abstract][Full Text] [Related]
9. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
10. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
[TBL] [Abstract][Full Text] [Related]
11. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
[TBL] [Abstract][Full Text] [Related]
12. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
[TBL] [Abstract][Full Text] [Related]
13. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
16. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
17. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
Siddiqui F; Hoppensteadt D; Jeske W; Iqbal O; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619847524. PubMed ID: 31088146
[TBL] [Abstract][Full Text] [Related]
18. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
[TBL] [Abstract][Full Text] [Related]
20. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
